Business Context and Reporting Period
This Form 8-K Current Report is filed by Propanc Health Group Corporation (also referenced as Propanc Biopharma, Inc.) for the reporting period ending December 23, 2016. The filing details the entry into a new material definitive agreement for debt financing and the termination of a prior equity financing agreement.
Key Financial Metrics and Obligations
- New Debt Financing: Entered into a Securities Purchase Agreement with Eagle Equities, LLC for two 8% convertible redeemable junior subordinated promissory notes, each with a principal amount of $157,500 (Total Principal: $315,000).
- Funding Status: The first note ($157,500) was funded with cash. The second note ("Eagle Back-End Note") was initially paid for by an offsetting promissory note issued by Eagle Equities to the Company ("Note Receivable"), which is due August 21, 2017.
- Conversion Terms: Both notes are convertible into common stock at a price equal to 60% of the lowest closing bid price for the ten trading days prior to conversion.
- Interest Rates: Standard interest rate is 8% per annum. Upon an event of default, the rate increases to 24% per annum or the highest rate permitted by law.
- Existing Obligations: A $20,000 unsecured junior subordinated promissory note ("Commitment Note") issued to GHS Investments, LLC remains outstanding, accruing interest at 5% and maturing six months from issuance.
- Liquidity and Cash Flow: The filing does not provide specific cash flow statements, balance sheet totals, or liquidity ratios. The immediate cash inflow is limited to the funding of the First Note ($157,500).
Material Changes Versus Prior Period
- Termination of Prior Agreement: The Company terminated an Equity Financing Agreement with GHS Investments, LLC effective December 27, 2016. This agreement had allowed GHS to purchase up to $7.0 million of common stock.
- Cancelled Obligations: Due to the termination, GHS will not pay the anticipated $250,000 to the Company, and the associated $250,000 "GHS Note" will not be issued.
- No Penalties: The termination of the GHS agreement did not result in any early termination fees or penalties.
Outlook, Risks, and Contingencies
- Contingent Funding: The "Eagle Back-End Note" and the corresponding "Note Receivable" are subject to cancellation if the Company's shares do not maintain a minimum trading price and aggregate dollar trading volume during the five days prior to funding.
- Default Risks: Events of default trigger immediate payment of principal and accrued interest, a penalty interest rate of 24%, and potential liquidated damages.
- Prepayment Restrictions: The First Note may be prepaid within 180 days subject to penalties. The Eagle Back-End Note cannot be prepaid. If the First Note is redeemed within the first six months, the Eagle Back-End Note is automatically cancelled.
- Unregistered Sales: The issuance of securities to Eagle Equities was conducted under Section 4(a)(2) of the Securities Act of 1933, exempt from registration requirements.
Investor Verification Checklist
- Verify the current trading price and volume of Propanc Health Group Corporation common stock to assess the likelihood of the Eagle Back-End Note funding conditions being met.
- Confirm the exact maturity date of the outstanding $20,000 Commitment Note to GHS Investments, LLC.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and the Promissory Notes (Exhibits 4.1 and 4.2) for specific default triggers and penalty calculations.
- Monitor whether the Company issues any further equity or debt instruments to replace the terminated $7.0 million GHS financing facility.